Why Yarrow Bioscience, Inc.’s (YARW) Stock Is Down 5.35%
As of Thursday, September 03, Yarrow Bioscience, Inc.’s YARW share price has dipped by 5.35%, which has investors questioning if this is right time to buy.Rosalio Madrigal
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Yarrow Bioscience, Inc. operates as a clinical-stage biotechnology company that engages in developing transformative therapies for autoimmune thyroid diseases. The company’s candidate, YB-101, is a humanized monoclonal antibody targeting the thyroid-stimulating hormone receptor (TSHR) for the treatment of Graves’ disease and thyroid eye disease. The company was incorporated in 2025 and is based in New York, New York.
Commentary & Analysis
Why Yarrow Bioscience, Inc.’s (YARW) Stock Is Down 5.60%
As of Wednesday, September 02, Yarrow Bioscience, Inc.’s YARW share price has dipped by 5.60%, which has investors questioning if this is right time to buy.Jenna Brashear
Why Yarrow Bioscience, Inc.’s (YARW) Stock Is Down 5.41%
As of Monday, August 31, Yarrow Bioscience, Inc.’s YARW share price has dipped by 5.41%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Why Yarrow Bioscience, Inc.’s (YARW) Stock Is Down 10.81%
As of Monday, August 31, Yarrow Bioscience, Inc.’s YARW share price has dipped by 10.81%, which has investors questioning if this is right time to buy.Tudor Pop
Why Yarrow Bioscience, Inc.’s (YARW) Stock Is Up 9.53%
As of Wednesday, August 26, Yarrow Bioscience, Inc.’s YARW share price has surged by 9.53%, which has investors questioning if this is right time to sell.Michael Rose
Financial Summary
| Share Statistics | YARW | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $80.8 | $289.2 | 19% |
|
| Shares Out (Mil) | 4.3 | 54.1 | 13% |
|
| Institutional Ownership | na | 93.1% | na |
|
| Float (Mil) | na | 42.2 | na |
|
| Beta | 2.08 | 0.94 | 93% |
|
| Avg Daily Volume (000s) | 54 | 451 | 30% |
|
| Price Change (52-week) |
na | 59.8% | na |
|
| Growth | YARW | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 14.1% | na |
|
| Net Income (5yr) | na | (10.1%) | na |
|
| EPS (5yr) | na | 15.9% | na |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | na | (15.6%) | na |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | YARW | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $37 | na |
|
| Net Income (TTM) (Mil) | ($284) | ($43) | 5% |
|
| EPS (TTM) | ($66.818) | ($1.500) | 1% |
|
| Operating Cash Flow (TTM) (Mil) | $1 | ($31) | 33% |
|
| Net Cash Flow (TTM) (Mil) | na | $2 | na |
|
| Long-Term Debt (Q1) (Mil) | $0 | $4 | 0% |
|
| Enterprise Value (Q1) (Mil) | na | $190 | na |
|
| Valuation | YARW | Industry Median |
Percentile (All Stocks) |
|
| P/B | na | 2.84 | na |
|
| P/E | na | 20.4 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.1 | na |
|
| Ratios | YARW | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 66.9% | na |
|
| Net Margin | na | (74.2%) | na |
|
| ROA | na | (47.8%) | na |
|
| ROE | 773.5% | (55.0%) | 100% |
|
| Liabilities to Assets | 5.5% | 29.7% | 3% |
|
| F-Score | 2 | 3 | na |
|
Yarrow Bioscience, Inc. did not pass any screens on 9/3/2026.
